- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/54 - Interleukines [IL]
Détention brevets de la classe C07K 14/54
Brevets de cette classe: 4076
Historique des publications depuis 10 ans
|
157
|
205
|
233
|
335
|
356
|
350
|
407
|
422
|
371
|
47
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1137 |
124 |
| Regeneron Pharmaceuticals, Inc. | 4505 |
81 |
| Xencor, Inc. | 400 |
62 |
| Altor BioScience, LLC | 76 |
58 |
| Immunitybio, Inc. | 485 |
58 |
| Board of Regents, The University of Texas System | 5989 |
47 |
| The Board of Trustees of the Leland Stanford Junior University | 6594 |
40 |
| The Trustees of the University of Pennsylvania | 4382 |
40 |
| Modernatx, Inc. | 1280 |
37 |
| Obsidian Therapeutics, Inc. | 78 |
34 |
| City of Hope | 1008 |
32 |
| National University of Singapore | 2533 |
32 |
| Memorial Sloan-Kettering Cancer Center | 1985 |
30 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2942 |
30 |
| Genentech, Inc. | 4040 |
29 |
| Yale University | 2461 |
29 |
| Deka Biosciences, Inc. | 42 |
29 |
| The Regents of the University of California | 20355 |
25 |
| Cytune Pharma | 39 |
25 |
| Janssen Biotech, Inc. | 1612 |
24 |
| Autres propriétaires | 3210 |